Good morning :)
Place Order
Add to Watchlist

Marksans Pharma Ltd

MARKSANS

Marksans Pharma Ltd

MARKSANS
Health CarePharmaceuticals
SmallcapWith a market cap of ₹13,132 cr, stock is ranked 462
High RiskStock is 3.94x as volatile as Nifty
290.752.12% (-6.30)
290.752.12% (-6.30)

Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Health CarePharmaceuticals
SmallcapWith a market cap of ₹13,132 cr, stock is ranked 462
High RiskStock is 3.94x as volatile as Nifty

How to use scorecard? Learn more

Health CarePharmaceuticals
SmallcapWith a market cap of ₹13,132 cr, stock is ranked 462
High RiskStock is 3.94x as volatile as Nifty

Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
39.346.30
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
51.226.550.48%

Forecast & Ratings

Detailed Forecast 
100%
Analysts have suggested that investors can buy this stock

from 3 analysts

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

Marksans Pharma Limited is a pharmaceutical company, which is engaged in the research, manufacturing and marketing of generic pharmaceutical formulations.

Get more out of Tickertape, Go Pro!

Customise key metrics, see detailed forecasts, download stock data and more

Forecasts

Price

Revenue

Earnings

Income

Balance Sheet

Cash Flow

Income Statement

Industry refers to the sub-sector this company belongs to.

Higher than Industry Revenue Growth

A higher-than-industry revenue growth represents increased potential for the company to increase their market share

Over the last 5 years, revenue has grown at a yearly rate of 17.27%, vs industry avg of 9.03%

Increasing Market Share

Market share is the percentage of an industry's total sales going to a particular company. It gives a general idea of the size of a company v/s its competitors

Over the last 5 years, market share increased from 0.46% to 0.59%

Higher than Industry Net Income

Net income is equal to net earnings (profit) less expenses. This number is an important measure of how profitable the company is

Over the last 5 years, net income has grown at a yearly rate of 32.62%, vs industry avg of 15.28%

Loading...

Financial YearFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024TTM
Total Revenue902.20774.18921.161,004.691,134.541,382.871,532.691,911.452,227.832,323.27
Raw Materialssubtract504.85506.68502.58517.91514.88731.33703.92927.751,111.981,782.95
Power & Fuel Costsubtract12.5812.9711.5513.9914.0016.4218.5924.5036.94
Employee Costsubtract122.42149.70147.75159.07168.42197.32220.30239.37293.64
Selling & Administrative Expensessubtract65.7865.1888.83109.58120.38154.55148.41227.00236.41
Operating & Other expensessubtract51.43-12.1283.6067.38124.28-63.05140.7494.2039.86
Depreciation/Amortizationsubtract28.1330.0926.8422.8026.6636.1544.7851.8574.2781.05
Interest & Other Itemssubtract10.166.7810.229.668.757.998.459.1311.2012.55
Taxes & Other Itemssubtract28.336.0616.8627.8436.4266.2262.9571.34109.83112.92
EPS1.920.220.801.872.955.764.516.186.927.37
DPS0.410.050.050.050.100.250.250.500.00
Payout ratio0.210.230.060.030.030.040.060.080.000.00

Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange
FY 2021

Annual report

PDF

Investor Presentation

May 31PDF
FY 2022

Annual report

PDF

Investor Presentation

May 30PDF
Feb 11PDF
Nov 10PDF
Aug 11PDF
FY 2023

Annual report

PDF

Investor Presentation

May 30PDF
Feb 13PDF
Nov 14PDF
Aug 13PDF
FY 2024

Annual report

PDF

Investor Presentation

Aug 11PDF
 

Peers & Comparison

Comparing 3 stocks from 
Health CarePharmaceuticals

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Marksans Pharma Ltd41.866.30
Sun Pharmaceutical Industries Ltd47.866.830.71%
Cipla Ltd31.814.890.80%
Torrent Pharmaceuticals Ltd70.9717.150.81%

Price Comparison

Compare MARKSANS with any stock or ETF
Compare MARKSANS with any stock or ETF
MARKSANS
Loading...

Shareholdings

Promoter Holdings Trend

Total Promoter Holding

Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding

Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Institutional Holdings Trend

Decreased Total Retail Holding

Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has decreased by 1.46%

Increased Foreign Institutional Holding

Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has increased by 3.02%

Tickertape Separator

Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding43.87%2.82%0.93%18.60%33.78%

Sep 2023

Dec 2023

Mar 2024

Jun 2024

Shareholding History

MarJunSepDec '23MarJun15.12%14.91%15.07%15.56%15.57%18.60%

Mutual Funds Holding Trend

Decreased Mutual Fund Holding

Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has decreased by 1.41%

Top 5 Mutual Funds holding Marksans Pharma Ltd




Funds (Top 5)Market-cap heldWeight3M holding changePortfolio rank
(3M change)
UTI Small Cap Fund - Direct Growth Plan

Growth
0.5972%1.68%0.61%51/97 (+14)
Kotak Special Opportunities Fund - Growth - Direct Plan

Growth
0.5155%2.79%2.79%12/40 (+22)
UTI Aggressive Hybrid Fund - Growth - Direct Plan

Growth
0.4290%0.89%0.19%61/102 (+7)

Compare 3-month MF holding change on Screener

Insider Trades & Bulk Deals

Loading...

smallcases

Looks like this stock is not in any smallcase yet.

Events

Dividend Trend

No dividend trend available

Dividends

Corp. Actions

Announcements

Legal Orders

Upcoming Dividends

No upcoming dividends are available

Past Dividends

Cash Dividend

Ex DateEx DateSep 17, 2024

Final
Final | Div/Share: ₹0.60

Dividend/Share

0.60

Ex DateEx Date

Sep 17, 2024

Cash Dividend

Ex DateEx DateJun 7, 2023

Final
Final | Div/Share: ₹0.50

Dividend/Share

0.50

Ex DateEx Date

Jun 7, 2023

Cash Dividend

Ex DateEx DateAug 19, 2022

Final
Final | Div/Share: ₹0.25

Dividend/Share

0.25

Ex DateEx Date

Aug 19, 2022

Cash Dividend

Ex DateEx DateSep 15, 2021

Final
Final | Div/Share: ₹0.25

Dividend/Share

0.25

Ex DateEx Date

Sep 15, 2021

Cash Dividend

Ex DateEx DateSep 22, 2020

Final
Final | Div/Share: ₹0.10

Dividend/Share

0.10

Ex DateEx Date

Sep 22, 2020

News & Opinions
Spotlight
Marksans Pharma gets EIR from USFDA for Goa facility

The inspection has been classified as voluntary action indicated (VAI) and has been closed accordingly, the firm added. Earlier, on 18 April 2024, the USFDA conducted good manufacturing practices (GMP) inspection at the company's facility located at Verna Industrial estate, Verna, Goa, India and issued five inspectional observations in Form 483. The inspection was conducted from 9 April to 17 April 2024. Marksans Pharma is primarily engaged in the business of research, manufacture, marketing and sale of pharmaceutical formulations. The pharma company reported 29.27% increase in consolidated net profit to Rs 88.75 crore in Q1 FY25 from Rs 68.66 crore in Q1 FY24. Revenue from operations jumped 18.12% YoY to Rs 590.62 crore in first quarter of FY25. The scrip rose 0.36% to Rs 221.30 on the BSE.Powered by Capital Market - Live

1 month agoCapital Market - Live
Corporate
Marksans Pharma's Verna unit successfully completes USFDA inspection

Marksans Pharma announced that he USFDA has issued an Establishment Inspection Report (EIR) for its manufacturing facility located at Verna, Goa and the inspection has now been successfully closed by the USFDA. USFDA has determined that the inspection classification of this facility is 'Voluntary Action Indicated' (VAI).Powered by Capital Market - Live

1 month agoCapital Market - Live
Corporate
Marksans Pharma to convene AGM

Marksans Pharma announced that the Annual General Meeting (AGM) of the company will be held on 24 September 2024.Powered by Capital Market - Live

1 month agoCapital Market - Live
Spotlight
Marksans Pharma surges after Q1 PAT rises 29% YoY to Rs 89 cr

Revenue from operations jumped 18.12% YoY to Rs 590.62 crore in first quarter of FY25, driven by new launches and increase in our share with existing customers in the key markets. Research & Development (R&D) spend stood at Rs 12 crore during the quarter, 2% of consolidated revenue. Profit before tax rose 23.95% to Rs 120.02 crore in June 2024 quarter as compared with Rs 96.83 crore posted in corresponding quarter previous fiscal. EBITDA climbed 26% to Rs 128.4 crore in Q1 FY25 as compared to Rs 102 crore in same period last year. EBITDA margin improved to 21.7% in Q1 of FY25 as compared to 20.4% in the corresponding period last year. During the quarter, revenue from US & North America stood at Rs 250.9 crore (up 29.8% YoY) and UK and Europe stood at Rs 251.5 crore (up 11.3% YoY). Revenue from Australia and New Zealand business stood at Rs 65.6 crore (down 12% YoY) in Q1 FY24. Rest of World (ROW) business grew by 2.1% YoY to Rs 22.7 crore during the period under review. In Q1 FY25, the capex incurred was Rs 31 crore, which is in line with the firm's plan for scaling the acquired manufacturing unit from Teva Pharma in Goa. The cash balance at the end of 30 June 2024 is at Rs 691 crore. In Q1 FY25, cash from operations was at Rs 45.3 crore and free cash flow was at 14.3 crore. The pharmaco received market authorization from UKMHRA for products Levonorgestrel 1.5mg tablets, Rasagiline 1mg tablets and Olmesartan 10, 20, 40mg tablets during the period under review. Mark Saldanha, managing director, Marksans Pharma, said, We are delighted to build on the growth momentum from the last year ' the first quarter of FY25 has shown strong start with 18% YoY increase in revenue and 26% YoY increase in EBITDA. The growth is supported by increase in share from existing customers and new launches. We experienced favorable raw material prices, however surge in freight costs continue. The shipments from the new facility have commenced to our key markets, and with that we remain optimistic for a stronger performance in the coming quarters, and our journey towards achieving the next revenue goal of Rs. 3,000 crores over the next two years.' Marksans Pharma is primarily engaged in the business of research, manufacture, marketing and sale of pharmaceutical formulations. Powered by Capital Market - Live

1 month agoCapital Market - Live
Earnings
Marksans Pharma consolidated net profit rises 29.26% in the June 2024 quarter

Net profit of Marksans Pharma rose 29.26% to Rs 88.75 crore in the quarter ended June 2024 as against Rs 68.66 crore during the previous quarter ended June 2023. Sales rose 18.12% to Rs 590.62 crore in the quarter ended June 2024 as against Rs 500.03 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales590.62500.03 18 OPM %21.7520.39 - PBDT140.46110.49 27 PBT120.0296.83 24 NP88.7568.66 29 Powered by Capital Market - Live

1 month agoCapital Market - Live
Corporate
Marksans announces receipt of marketing authorization for Levonorgestrel 1.5 mg Tablets

Marksans Pharma announced that its wholly owned subsidiary Relonchem has received Marketing Authorization for the product Levonorgestrel 1.5 mg Tablets from UK MHRA. Levonorgestrel, also known as the morning-after pill, is a first-line oral emergency contraceptive pill. It is to be used within 72 hours of unprotected sexual intercourse or when a presumed contraceptive failure has occurredPowered by Capital Market - Live

2 months agoCapital Market - Live
Corporate
Marksans Pharma to table results

Marksans Pharma will hold a meeting of the Board of Directors of the Company on 13 August 2024.Powered by Capital Market - Live

2 months agoCapital Market - Live

Raymond Ltd leads gainers in ‘A’ group

3 months agoBusiness Standard
Marksans Pharma: Stock Recommendation, Company's Fundamentals, & Target By Sandeep Jain
7 months agoZee Business
Top Stocks In Focus Today | Granules India, Birla Soft, Marksans Pharma | Dhwani Patel
11 months agoET NOW